REGEN COV Therapy as the Basis of Mixed Immunomodulatory Therapy in Patients Hospitalized for SARS- CoV-2 Pneumonia: Case Series
Article Sidebar
Main Article Content
Abstract
Introduction: developing countries with low-investment health systems find it challenging to prioritize COVID-19 treatment according to its efficacy and affordability.
Materials and methods: therefore, the in-hospital utility of a safe intervention with outpatient efficacy is explored. We describe the administration of immunomodulatory combination therapy based on imdevimab and casirivimab (REGEN COV).
Results: individualized results point to promising outcomes in patients at high risk of progression and mortality.
Conclusion: REGEN COV has been shown to be efficient in treating said disease. However, randomized clinical trials are needed to verify their efficacy in combination.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Khetrapal S, Bhatia R. Impact of COVID-19 pandemic on health system & Sustainable Development Goal 3. Indian J Med Res 2020;151(5):395-399. Doi: 10.4103/ijmr.IJMR_1920_20.
Parums DV. Editorial: Post-Exposure Prophylactic Neutralizing Monoclonal Antibodies to SARS-CoV-2 for Individuals at High Risk for COVID-19. Med Sci Monit 2021;27:e934393. Doi: 10.12659/MSM.934393.
Copin R, Baum A, Wloga E et al. The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies. Cell 2021;184(15):3949-61. Doi: 10.1016/j.cell.2021.06.002
O’Brien MP, Forleo-Neto E, Musser BJ et al. Subcutaneous REGEN-COV antibody combination to prevent Covid-19. N Engl J Med 2021;385(13):1184-95. Doi: 10.1056/NEJMoa2109682
Somersan-Karakaya S, Mylonakis E, Menon VP et al. REGEN-COV® for Treatment of Hospitalized Patients with Covid-19. medRxiv 2021. Doi: 10.1101/2021.11.05.21265656
Abani O, Abbas A, Abbas F et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet 2022;399(10325):665-76. Doi: 10.1016/S0140-6736(22)00163-5
Águila-Gordo D, Martínez-del Río J, Mazoteras-Muñoz V, Negreira-Caamaño M, Piqueras-Flores J. Mortalidad y factores pronósticos asociados en pacientes ancianos y muy ancianos hospitalizados con infección respiratoria COVID-19. Revista Española de Geriatría y Gerontología 2021;56(5):259-67. Doi: 10.1016/j.regg.2020.09.006
Hayek S, Ben-Shlomo Y, Dagan N et al. Effectiveness of REGEN-COV antibody combination in preventing severe COVID-19 outcomes. Nature Communications 2022;13(1):1-5. Doi: 10.1038/s41467-022-32253-9
Gottlieb RL, Vaca CE, Paredes R et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med 2022;386(4):305-15. Doi: 10.1056/NEJMoa2116846.
Ader F, Bouscambert-Duchamp M, Hites M et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. The Lancet Infectious Diseases 2022;22(2):209-21. Doi: 10.1016/S1473-3099(21)00485-0
Rosas IO, Diaz G, Gottlieb RL et al. Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial. Intensive Care Med 2021;47(11):1258-70. Doi: 10.1007/s00134-021-06507-x
Bermúdes AA, Zambrano LA, Illescas DI, Almeida JF. Anticoagulación vs profilaxis en COVID-19. RECIMUNDO 2021;5(2):140-8. Doi: 10.26820/recimundo/5.(2).abril.2021.140-148
Gómez-Mesa JE, Montenegro AC, Gálvez KM et al. Tromboprofilaxis, anticoagulación y coagulopatía en tiempos de pandemia: recomendación de la ACATA, ACMI, SCC CCV y ACMV. Rev Colomb Cardiol 2021;28(6):539-47. Doi: 10.24875/rccar.m21000095
Maslennikov R, Ivashkin V, Vasilieva E et al. Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19. Pulm Pharmacol 2021;69:102039. Doi: 10.1016/j.pupt.2021.102039
Guimarães PO, Quirk D, Furtado RH et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. N Engl J Med 2021;385(5):406-15. Doi: 10.1056/NEJMoa2101643